[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613058":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":34,"responsibleParty":53,"collaborators":25,"id":55,"slug":25,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":25,"enrollmentInfo":63,"targetDuration":25,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":25,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"608 Dose","EXPERIMENTAL","608 subcutaneous (SC) injection.",[13],"Drug: 608 dose",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo subcutaneous (SC) injection.",[19],"Drug: Placebo",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","608 dose",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Qing hong Zhou","CONTACT","+86 18911301578","zhouqinghong@3sbio.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Site 01","RECRUITING","Beijing","Beijing Municipality","100730","China",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":51,"phoneExt":25,"email":52},"Zeng Xiao feng MD","+86 13501069845","Xiaofeng.zeng@cstar.org.cn",{"type":54,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100613058",false,"NCT07261644","A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis (AS)","Inclusion Criteria:\n\n1. Able to understand and comply with the protocol requirements, participate and sign the informed consent form (ICF) voluntarily;\n2. At least 18 years of age at the time of signing the ICF, with no gender restrictions;\n3. Meet the 1984 modified New York criteria for ankylosing spondylitis (AS);\n4. Have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) or have contraindications\u002Fintolerance to NSAIDs treatment;\n5. Willing to practice contraception and have no plans for pregnancy, sperm donation, or egg donation from the screening period until at least 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Patients with other uncontrolled active inflammatory diseases.\n2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance\n3. Patients who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening.\n4. History of cancer.\n5. Known or suspected history of immunosuppression.","ALL","18 Years",{"count":64,"type":65},500,"ESTIMATED","INTERVENTIONAL",[68],"PHASE3","This study will evaluate the efficacy and safety of 608 in patients with AS.",[71],"Ankylosing Spondylitis","2025-12-03",{"date":74,"type":75},"2025-12-10","ACTUAL",{"date":77,"type":75},"2025-11-07",{"date":79,"type":65},"2027-11-18",{"name":5,"class":6},1]